• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas H. Rea, MD

Arch Dermatol. 1979;115(3):361-362.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Enhancement of dinitrochlorobenzene (DNCB) responsivity by estrogen-progestin combination oral contraceptives or by parenteral progestins was reported by Gerretsen et al.¹ Because of a possible influence of contraceptive use on either controls or patients in studies using DNCB, this observation warranted attempted confirmation. Furthermore, the apparent but unexplained protective effect of oral contraceptive use on the incidence of rheumatoid arthritis emphasized the importance of careful study of any immunologic influence of this widely used medication.²

Patients and Methods

Sensitization with DNCB was attempted in 13 women receiving estrogen-progestin combination oral contraceptives for the purpose of contraception, 20 women of similar ages receiving neither estrogens nor progestins, and 16 men of similar ages. The subjects were clinic patients, hospital employees, or medical students judged to be in good general health, without disease, and not taking medications known to influence immunologic responses. Blacks were not included in this study because of . . . [Full Text PDF of this Article]

Author Affiliations

Footnotes

Reprint requests to 1200 N State St, Los Angeles, CA 90033 (Dr Rea).

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?